Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Ségolène Bisot-Locard"'
Autor:
Mirela-Diana Ilie, Antoine Tabarin, Alexandre Vasiljevic, Jean-François Bonneville, Lucile Moreau-Grangé, Franck Schillo, Brigitte Delemer, Anne Barlier, Dominique Figarella-Branger, Ségolène Bisot-Locard, Alexandre Santos, Philippe Chanson, Gérald Raverot
Publikováno v:
Journal of Clinical Endocrinology and Metabolism
Journal of Clinical Endocrinology and Metabolism, 2022, 107 (11), pp.2982-2991. ⟨10.1210/clinem/dgac512⟩
Journal of Clinical Endocrinology and Metabolism, 2022, 107 (11), pp.2982-2991. ⟨10.1210/clinem/dgac512⟩
Context Somatostatin receptor ligands (SRLs) are the cornerstone medical treatments for acromegaly; however, many patients remain unresponsive to SRLs. Well-established predictive markers of response are needed. Objective We aimed to explore the rela
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5df7c83a16a040eebb37a92e2d449b5
https://doi.org/10.1210/clinem/dgac512
https://doi.org/10.1210/clinem/dgac512
Autor:
Guillaume Cadiot, Denis Smith, Thierry Nguyen-Tan-Hon, Brigitte Delemer, F Schillo, Bénédicte Decoudier, Pierre-Luc Etienne, Romain Coriat, Alexandre Santos, Isabelle Raingeard, Ségolène Bisot-Locard, Iradj Sobhani, Gérald Raverot
Publikováno v:
Advances in Therapy. 37:3901-3915
The first long-acting release (LAR) formulation of octreotide was marketed in France in the late 1990s. An injectable formulation of Sandostatin LAR® (Novartis SAS) with a new diluent has been developed to facilitate its preparation and administrati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b64ee0d76fea71b45c17a4067a104f1b
https://doi.org/10.1007/s12325-020-01429-4
https://doi.org/10.1007/s12325-020-01429-4
Autor:
Denis Smith, Côme Lepage, Eric Vicaut, Sophie Dominguez, Romain Coriat, Olivier Dubreuil, Thierry Lecomte, Eric Baudin, Laurence Venat Bouvet, Emmanuelle Samalin, Alexandre Santos, Odile Borie, Ségolène Bisot-Locard, Bernard Goichot, Catherine Lombard-Bohas
Publikováno v:
Advances in therapy. 39(6)
Approval of sunitinib and everolimus for the treatment of progressive, unresectable or metastatic well-differentiated pancreatic neuroendocrine tumors (pNETs) was obtained in France in 2011 and 2012, respectively. OPALINE was set up as an observation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a310a8cd58ac30751cf0573ca853e48b
https://pubmed.ncbi.nlm.nih.gov/35419649
https://pubmed.ncbi.nlm.nih.gov/35419649
Autor:
Brigitte, Delemer, Thierry, Nguyen-Tan-Hon, Romain, Coriat, Denis, Smith, Frank, Schillo, Isabelle, Raingeard, Iradj, Sobhani, Pierre-Luc, Etienne, Benedicte, Decoudier, Ségolène, Bisot-Locard, Alexandre, Santos, Gerald, Raverot, Guillaume, Cadiot
Publikováno v:
Advances in therapy. 37(9)
The first long-acting release (LAR) formulation of octreotide was marketed in France in the late 1990s. An injectable formulation of Sandostatin LARWe conducted an observational, cross-sectional and multicenter study in France whose main outcome was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7a9d96db1bf3fcff0cdc3bd9b7db3f02
https://pubmed.ncbi.nlm.nih.gov/32683667
https://pubmed.ncbi.nlm.nih.gov/32683667
Autor:
Frank Priou, Jean-Yves Blay, Stéphane Remy, Thierry Lecomte, Sylvain Manfredi, Nicolas Isambert, Roland Sambuc, Thomas Aparicio, Axel Le Cesne, Maria Rios, Olivier Bouché, Dominique Arsene, Olivier Bourges, Loic Chaigneau, Antoine Italiano, Florence Duffaud, Olivier Collard, François Bertucci, Sylvie Chabaud, Ségolène Bisot-Locard
Publikováno v:
PLoS ONE, Vol 13, Iss 9, p e0204117 (2018)
PLoS ONE
PLoS ONE, Public Library of Science, 2018, 13 (9), pp.e0204117. ⟨10.1371/journal.pone.0204117⟩
PLoS ONE
PLoS ONE, Public Library of Science, 2018, 13 (9), pp.e0204117. ⟨10.1371/journal.pone.0204117⟩
Background Gastrointestinal stromal tumors (GISTs) are rare, but represent the most common mesenchymal neoplasms of the gastrointestinal tract. EPIdemiology GIST, is an observational multicenter longitudinal follow-up cohort study reporting the presc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::157e41116c674b2440b9f84a81701728
http://europepmc.org/articles/PMC6143255?pdf=render
http://europepmc.org/articles/PMC6143255?pdf=render
Autor:
Serge Guyétant, Anne Couvelard, Xavier Parot, Ségolène Bisot-Locard, Côme Lepage, Geneviève Monges, Jean-Yves Scoazec
Publikováno v:
Neuroendocrinology
Neuroendocrinology, Karger, 2017, 105 (1), pp.67-76. 〈https://www.ncbi.nlm.nih.gov/pubmed/?term=Professional+Practices+and+Diagnostic+Issues+in+Neuroendocrine+Tumour+Pathology%3A+Results+of+a+Prospective+One-Year+Survey+among+French+Pathologists+(the+PRONET+Study)〉. 〈10.1159/000448431〉
Neuroendocrinology, Karger, 2017, 105 (1), pp.67-76. ⟨10.1159/000448431⟩
Neuroendocrinology, Karger, 2017, 105 (1), pp.67-76. 〈https://www.ncbi.nlm.nih.gov/pubmed/?term=Professional+Practices+and+Diagnostic+Issues+in+Neuroendocrine+Tumour+Pathology%3A+Results+of+a+Prospective+One-Year+Survey+among+French+Pathologists+(the+PRONET+Study)〉. 〈10.1159/000448431〉
Neuroendocrinology, Karger, 2017, 105 (1), pp.67-76. ⟨10.1159/000448431⟩
Introduction: Many changes have recently occurred in the practice of neuroendocrine tumour (NET) pathology. We therefore aimed to evaluate how pathologists have adapted their daily practice to the most recent international guidelines for diagnostic a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f046b00b5f37cf1de07cbc520106c98
https://hal-univ-bourgogne.archives-ouvertes.fr/hal-01576206
https://hal-univ-bourgogne.archives-ouvertes.fr/hal-01576206
Autor:
Guillemette, Laval, Hubert, Rousselot, Sophie, Toussaint-Martel, Françoise, Mayer, Eric, Terrebonne, Eric, François, Hédia, Brixi, Thierry, Nguyen, Isabelle, Bourdeix, Ségolène, Bisot-Locard, Laurent, Zelek, Karine, Moutel
Publikováno v:
Bulletin du Cancer. 99:E1-E9
This phase II, multicenter, randomized, double-blind, non-comparative study assessed the efficacy and safety of immediate-release octreotide and octreotide LAR, in combination with corticosteroids and standard medical care, on the symptoms of inopera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18e6d9ce7b29cf052632d50a6786b06f
https://doi.org/10.1684/bdc.2011.1535
https://doi.org/10.1684/bdc.2011.1535
Autor:
Ariel Beresniak, Xavier Bresse, Erick Legrand, Anne-Marie Vigneron, Patrice Fardellone, Bernard Cortet, Ségolène Bisot-Locard
Publikováno v:
Revue du Rhumatisme. 77:63-67
Resume Objectifs Comparer l’efficacite, les couts epargnes et le rapport cout-efficacite d’une unique perfusion annuelle d’acide zoledronique versus les strategies therapeutiques usuelles de prise en charge de l’osteoporose post-menopausique
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::36910ef1cd6b5a99627cb6a8dc663c84
https://doi.org/10.1016/j.rhum.2009.11.003
https://doi.org/10.1016/j.rhum.2009.11.003
Autor:
Brigitte Pégourié-Bandelier, Annabelle Merlat-Guitard, Maya Hacini, Ségolène Bisot-Locard, Martine Gardembas-Pain, Dora Bachir, Isabelle Thuret
Publikováno v:
Hematology. 14:315-322
Deferoxamine (DFO) is an iron chelator used to treat iron overload in patients receiving chronic blood transfusions, and is usually administered as overnight subcutaneous infusions. ISOSFER was a prospective, observational, cross-sectional study cond
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12a26154ce87ad6b67d0110b4b2a690f
https://doi.org/10.1179/102453309x12473408860424
https://doi.org/10.1179/102453309x12473408860424
Autor:
Yves Reznik, B. Delemer, C Reines, P. Chanson, Christine Cortet-Rudelli, Françoise Borson-Chazot, Georges Weryha, I. Raingeard, L Foubert, Frederic Castinetti, A. Tabarin, Ségolène Bisot-Locard, Olivier Chabre
Publikováno v:
European journal of endocrinology. 170(5)
ObjectiveThe complex management of acromegaly has transformed this disease into a chronic condition, with the risk of patients being lost to follow-up. The objective of this study was to estimate the proportion of acromegalic patients lost to follow-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf90e0ebd9ae49db2a8c29c8e8ae63d3
https://pubmed.ncbi.nlm.nih.gov/24591552
https://pubmed.ncbi.nlm.nih.gov/24591552